Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.

Slides:



Advertisements
Similar presentations
Welcome to the Open Court Business Plan Executive Summary Template!
Advertisements

The TB Alliance-Bayer Moxifloxacin Deal
IMS LifeCycle – R&D Focus Patent Focus and New Product Focus Product developments since 2004.
SLA – Pipeline Town Hall Ben Weintraub and Jeff Southwood
Name of institute or company
Title Slide Name of your business Your name or presenter’s name
Technology Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. ( Vice President for Affiliate Members Association.
ONLINE BUSINESS. Business Plan for Online Business  What Is Included In A Business Plan? There are four main parts to a business plan: 1. the description.
The Statisticians Role in Pharmaceutical Development
Technology and Economic Development Intellectual Property Issues in Research Jim Baker Director Office of Technology and Economic Development
1 Confidential Science of Stem Cells and Potential Applications Andrea Hunt February 22, 2008.
Commercializing Discoveries: Disclosing your Intellectual Property By Ryan N. Fiorini, Ph.D., MBA, MHA Licensing and Commercialization Manager MUSC Foundation.
Preparing Your Business Plan
Writing a Winning Business Plan. A business plan is a strategy for creating, launching and managing a new venture. It answers the questions of A business.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Capturing Innovation: Turning Intellectual Assets into Business Assets Justin Woo IEOR 190G - Patent Engineering Professor Tal Lavian Project #2 – Chapter.
Confidential Presenting Gonexin December 13, 2001 Providing hope through extension and enhancement of life MBA Consulting Team Larry Morkre Matt Narens.
Business Plans For The Real World Barry Williams Delaware SBDC.
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.
Academic Clinical Trial Do’s & Don’ts for Partnering with Pharma CCAF San Diego, CA April 14, 2014 J. Eric Bubbers, Ph.D.
Stages of drug development
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
Product/Service Name: Team Leader: Faculty / Research Alliance: Mobile Tel:
Business Plans For The Real World. Why a Business Plan? Strategic Guide Lenders Investors.
Overview OTL Mission Inventor Responsibility Stanford Royalty Sharing Disclosure Form Patent View Inventor Agreements Patent.
Technology Transfer and Assessment of Intellectual Assets Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. ( Vice President.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
1 Michael V. Novinski President and Chief Executive Officer November 6, 2008 Third Quarter 2008 Earnings Conference Call.
Invention Disclosure Analysis / Triage. Overview Decision making Components of an invention disclosure Review process Qualitative factors – art vs. science.
Enter the Title of Your Presentation Lead Inventors Name Other Inventors Name Purpose: Enter why you are coming to patent committee (initial filing, PCT,
Browse more reports on research/pharmaceuticals/ research/pharmaceuticals/
Patent Citation and the Economic Value of a Patent Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. ( Workshop on Competitiveness.
Licensing Early-Stage Academic Technologies to the Pharmaceutical Industry: Some Dos and Don’ts to Improve Success Gerald J. Siuta, Ph.D. President Siuta.
Browse more reports on Pharmaceuticals at sciences/pharmaceuticalshttp://
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Intellectual Property Rights and Pharmaceutical Industry
Ignite Technology Transfer NUI Galway Technology Transfer Office Seamus Coyne, Ph.D Neil Ferguson, Ph.D Commercialisation Executives Technology Transfer.
Enter the Title of Your Presentation Lead Inventors Name Other Inventors Name Purpose: Enter why you are coming to patent committee (initial filing, PCT,
Office of Technology Development Case No. ________ CONFIDENTIAL Intellectual Property Committee Presentation Inventor(s) Invention Title Presentation Guidelines:
Project Title Investigators 1 To see TIPS and FAQS for each slide, please look at this template in Notes view.
“Journey of a Drug” From Test Tube TO Prescribing Physician.
Intellectual Property at USC October 27, 2003 Dr. Michael Muthig.
VOLT01 Reformulated Zoledronic Acid Targeted to be the first Disease- Modifying Drug in Osteoarthritis.
Biosimilar (Insulin) – Competitive Landscape and Market & Pipeline Analysis, 2016 DelveInsight’s, “Biosimilar (Insulin) – Competitive Landscape and Market. Request for sample of this research report:
Develop a Marketing Plan.  Your marketing plan gives you a guide on which to base decisions and ensures that everyone is working together to achieve.
Nippon Shinyaku Co., Ltd. - Product Pipeline Review Published on : October
Business Description Provide a short executive summary of your company (2 slides max.- inc. Short history, Key products, Investors, Funding, Awards)
Browse more Reports on Biotechnology at
Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations.
Presentation by Dr. Andreas O. Tobler September 1, 2011 Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.
Browse more reports on Autoimmune Drugs at treatment/autoimmune-drugshttp://
Browse more Reports on Neurology Therapeutics at therapeuticshttp://
PRESENTATION attached to the application for participation in the Competitive Selection dated_____________________ Innovation Project: […] Entity: […]
[Business/Concept Name] [Presenter, Key Personnel] ***Remember as you draft your slides that there is a hard 12 minute stop on your presentation***
Cognitive Impairment Associated With Schizophrenia (CIAS)Pipeline Review, H Published on : October No. Pages : 110.
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Five Prime Therapeutics, Inc. Product Pipeline Review Published on : October No. Pages : 44.
Browse more reports on research/pharmaceuticals/ research/pharmaceuticals/
1 Communicating with Venture Capitalists to Fund Your Research Raising Venture Capita l Michael Jirousek, Ph.D. Senior Advisor, Innovation Support Center.
Moxifloxacin Development in TB Dr. Martin Springsklee VP, Therapeutic Area Head, Clinical Development Anti-Infectives Bayer HealthCare AG GATB Annual Stakeholder.
Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2016 MarketIntelReports, “Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2016”,
Skolkovo PRESENTATION
Initial Market Assessment
SPARC – Washington University LEAP Inventor Challenge Program RFP
Pharmaceuticals Industry
Proposal Presentation to the
Project title Company name.
Presentation transcript:

Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001

What Are the Keys to the Commercialization of Technology? Marketable technology A commercialization partner Siuta Consulting, Inc.

Setting the Stage for Licensing When to seek a partner: When you have A patentable invention Commercial potential When you require Financial support Development capabilities Marketing assistance Siuta Consulting, Inc.

What Do Companies Want? New chemical entities Demonstrated biological activity In vitro activity In vivo activity Novel mechanism of action Improved therapeutic index New drug targets Patented technology Siuta Consulting, Inc.

Assess Commercial Potential Therapeutic indication Chronic vs. acute therapy Mode of administration and dosing schedule Market size and sales potential Advantages over competitive products Product price and profit margin Development timeline and costs Patent status Siuta Consulting, Inc.

Technologies with Reduced Marketability New uses For an old compound For a currently marketed drug Combination product Preventives vs. treatments Me-too product Large molecules Peptides and proteins Siuta Consulting, Inc.

Enhancing the Value and Increasing the Chance For Commercialization Get broad patent coverage Perform well designed experiments Assay reliability Quality vs. quantity Use suitable controls Avoid quick and dirty No anecdotal clinical data Siuta Consulting, Inc.

Potential Partners Target Companies that: Market similar products Have research programs in the same area Have the capability to develop the product Are seeking to enhance their pipeline Are committed to technology transfer Siuta Consulting, Inc.

Finding a Licensee Faculty colleagues Pharmaprojects Physicians Desk Reference Annual reports Technology transfer databases Personal industrial contacts Siuta Consulting, Inc.

Initial Presentation of the Data: The Executive Summary Title Summary paragraph Brief description of the invention Potential therapeutic indications Identify inventor Background Scientific rationale for the technology Siuta Consulting, Inc.

Initial Presentation of the Data: The Executive Summary (continued) Detailed description of the invention Summary of available data Stage of development Potential advantages Comparison to known drugs Publications Scientific journals Meeting presentations Siuta Consulting, Inc.

Initial Presentation of the Data: The Executive Summary (continued) Patent status What is claimed Where have patents issued Where have applications been filed Licensing status What is being sought from a partner Siuta Consulting, Inc.

Pitfalls to Avoid Pursue licensing before technology is sufficiently developed Publish before filing patent applications File patent applications too early Fail to file patent applications worldwide Mistake new use for new chemical entity Overestimate the value Siuta Consulting, Inc.

Probability of Success 10,000 compounds synthesized 1,000 will reach animal studies 10 will reach Phase I 5 will reach Phase II 1 will reach Phase III 0.9 will achieve FDA approval Siuta Consulting, Inc.